Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD84 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Gyala Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-CD84 CAR-T cells are chimeric antigen receptor T-cell therapies genetically engineered to recognize and kill cancer cells expressing the CD84 antigen. CD84, a member of the SLAM family (SLAMF5), is overexpressed on leukemic blasts in acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL), with minimal expression on healthy hematopoietic stem progenitor cells (HSPC) and low presence in normal tissues. This therapy uses autologous or allogeneic T-cells modified with second-generation CAR constructs comprising anti-CD84 single-chain variable fragments (scFv) and 4-1BB co-stimulatory domains. Preclinical data show potent cytotoxicity against AML and T-ALL in vitro and in vivo, with low off-tumor toxicity to HSPC, supporting clinical trial development for relapsed/refractory AML and T-ALL as a potential bridge to transplant. The developer is Gyala Therapeutics, with ongoing clinical development in Spain[1][3][5].
- Other names
- CD84-targeted CAR-T cellsCD-84-targeted CAR-T cellsCD 84-targeted CAR-T cells
02
Targets
SLAMF5 (Signaling lymphocyte activation molecule family member 5)
Beyond the preview
Go deeper on anti-CD84 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD84 CAR-T cells.